- Home
- PLRX vs VINP Comparison
PLRX vs VINP Comparison
Compare PLRX & VINP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLRX | VINP |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.3M | 807.6M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PLRX | VINP |
|---|---|---|
| Price | $1.23 | $13.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 2 |
| Target Price | $3.79 | ★ $13.50 |
| AVG Volume (30 Days) | ★ 1.9M | 45.9K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | ★ 4.61% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.50 |
| Revenue | N/A | ★ $180,689,571.00 |
| Revenue This Year | N/A | $67.12 |
| Revenue Next Year | N/A | $15.14 |
| P/E Ratio | ★ N/A | $25.93 |
| Revenue Growth | N/A | ★ 100.47 |
| 52 Week Low | $1.10 | $8.66 |
| 52 Week High | $13.71 | $13.37 |
Technical Indicators
Market Signals| Indicator | PLRX | VINP |
|---|---|---|
| Relative Strength Index (RSI) | 39.68 | 60.25 |
| Support Level | $1.20 | $12.77 |
| Resistance Level | $1.27 | $13.21 |
| Average True Range (ATR) | 0.06 | 0.29 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 22.58 | 47.95 |
Price Performance
Historical ComparisonAbout PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About VINP Vinci Partners Investments Ltd.
Vinci Compass Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.